Fig. 2: Clonogenic cell survival, apoptosis, micronucleus formation, and release of DAMPs.

a Clonogenic survival was assessed in Ramos and DOHH2 cells at day 12 after exposure to rituximab or lilotomab (0–40 µg/mL), or ¹⁷⁷Lu-lilotomab (0–6 MBq/mL; 0–40 µg/mL) for 18 h. b Apoptosis in Ramos, DOHH2 and Rec-1 cells was measured using the Annexin V-FITC/7-AAD Kit and flow cytometry at different time points during and after exposure to 40 µg/mL of lilotomab or rituximab, or 6 MBq/mL of ¹⁷⁷Lu-lilotomab for 18 h and in nontreated cells (NT). c Micronucleus formation was measured in Ramos and DOHH2 cells at day 3 after exposure to 40 µg/mL rituximab or to 6 MBq/mL ¹⁷⁷Lu-lilotomab (left panel). Immunogenic cell death was assessed by quantifying ATP and HMGB1 release from Ramos cells exposed to¹⁷⁷Lu-lilotomab or rituximab (right panel). Results are the mean ± SD of three experiments performed in triplicate.